MedTrace Logo

A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers

NCT05337735 · Status: SUSPENDED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 140

Last updated 2026-05-04

No results posted yet for this study

Summary

To test the safety of and effectiveness of XmAb20717 for participants with advanced rare cancers.

Conditions

  • Microsatellite High Cancers
  • Peritoneal Mesothelioma
  • Extrapulmonary High Grade
  • Neuroendocrine Carcinomas
  • Cervical Carcinoma
  • Hodgkin's Lymphoma
  • Pleural Mesothelioma
  • Small Cell Lung Cancer

Interventions

DRUG

XmAb20717

Given by vein (IV)

Sponsors & Collaborators

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Arvind Nageshwara Dasaru, MD · M.D. Anderson Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-05
Primary Completion
2026-12-30
Completion
2026-12-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05337735 on ClinicalTrials.gov